PIRS Stock Price, Pieris Pharmaceuticals Quote, Chart

Market Summary

USD10.97-0.28

Delayed

-2.49%

PIRS Stock Price

View Fullscreen

PIRS RSI Chart

PIRS Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-66.78

Price/Sales (Trailing)

25.32

EV/EBITDA

-47.1

Price/Free Cashflow

-21.73

PIRS Price/Sales (Trailing)

PIRS Profitability

EBT Margin

-57.26%

Return on Equity

-73.99%

Return on Assets

-55.1%

Free Cashflow Yield

-4.6%

PIRS Fundamentals

PIRS Revenue

Revenue (TTM)

42.9M

Rev. Growth (Yr)

-78.75%

Rev. Growth (Qtr)

-93.61%

PIRS Earnings

Earnings (TTM)

-16.3M

Earnings Growth (Yr)

62.89%

Earnings Growth (Qtr)

-6.72%

Breaking Down PIRS Revenue

Last 7 days

-1.6%

Last 30 days

-12.7%

Last 90 days

-12.1%

Trailing 12 Months

-84.0%

How does PIRS drawdown profile look like?

PIRS Financial Health

Current Ratio

5.13

PIRS Investor Care

Shares Dilution (1Y)

9549.95%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	16.7M	33.3M	47.5M	42.9M
2022	27.0M	27.1M	28.5M	25.9M
2021	31.7M	23.7M	24.9M	31.4M
2020	51.0M	56.9M	44.7M	29.3M
2019	33.5M	27.1M	33.9M	46.3M
2018	28.1M	37.9M	42.3M	29.1M
2017	5.9M	6.7M	9.8M	25.3M
2016	4.0M	4.9M	5.2M	5.8M
2015	4.2M	3.7M	4.1M	2.9M
2014	10.7M	8.9M	7.1M	5.4M
2013	0	0	11.9M	12.4M
2012	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pieris Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 25, 2023	kiritsy christopher p	bought	8,500	0.85	10,000	-
May 13, 2022	demuth tim	bought	10,260	1.71	6,000	chief medical officer
Aug 30, 2021	olwill shane	sold	-196,380	5.11406	-38,400	chief development officer
Aug 30, 2021	olwill shane	acquired	58,368	1.52	38,400	chief development officer
Jul 21, 2020	aquilo capital management, llc	sold	-5,605,000	2.95	-1,900,000	-
Sep 06, 2019	bvf partners l p/il	sold	-224,970	4.4994	-50,000	-
Jan 30, 2019	bvf partners l p/il	sold	-	-	-5,000,000	-

Which funds bought or sold PIRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	B. Riley Wealth Advisors, Inc.	new	-	5,066	5,066	-%
May 15, 2024	Lynx1 Capital Management LP	reduced	-10.2	-170,863	1,608,340	0.42%
May 15, 2024	Squarepoint Ops LLC	new	-	26,717	26,717	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	426	6,345	7,822	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-2.02	-87.00	6,210	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	277	7,868	10,674	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	27.03	8,455	38,792	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-7,446	-	-%
May 15, 2024	BVF INC/IL	unchanged	-	24,732	3,775,730	0.10%
May 15, 2024	Royal Bank of Canada	reduced	-52.45	-	-	-%

Are Funds Buying or Selling PIRS?

Are funds buying PIRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PIRS

No. of Funds

Unveiling Pieris Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	checkpoint capital l.p.	0%	0	SC 13G/A
Feb 14, 2024	aquilo capital management, llc	1.1%	1,126,761	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	9.9%	9,775,849	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	0.0%	0	SC 13G/A
Aug 17, 2023	biotechnology value fund l p	11.1%	11,007,420	SC 13D/A
Jun 12, 2023	checkpoint capital l.p.	6.0%	4,938,486	SC 13G
May 22, 2023	biotechnology value fund l p	11.8%	11,007,420	SC 13D
Feb 14, 2023	aquilo capital management, llc	5.5%	4,134,009	SC 13G/A
Feb 14, 2023	lynx1 capital management lp	7.6%	5,628,585	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	6.0%	4,623,054	SC 13G/A

Recent SEC filings of Pieris Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13G	Major Ownership Report
May 17, 2024	SC 13G	Major Ownership Report
May 15, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Pieris Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Pieris Pharmaceuticals Inc News

Latest updates

Pieris Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	1,246,500	19,520,000	20,086,000	2,010,000	5,865,000	5,370,000	3,468,000	11,180,000	8,443,000	4,057,000	3,285,000	15,633,000	1,877,000	2,939,000	11,246,000	13,261,000	17,270,000	15,132,000	5,332,000	8,545,000
Operating Expenses	-7.7%	5,356,000	5,800,000	31,327,000	17,992,000	17,447,000	17,365,000	17,538,000	16,028,000	18,445,000	19,442,000	23,069,000	20,046,000	20,692,000	14,288,000	15,938,000	15,901,000	17,117,000	18,600,000	18,046,000	17,562,000	19,228,000
S&GA Expenses	-100.0%	-	2,327,000	6,839,000	3,664,000	4,023,000	3,985,000	3,949,000	4,081,000	4,379,000	4,085,000	4,132,000	4,246,000	4,130,000	3,670,000	4,116,000	4,568,000	4,359,000	4,484,000	4,835,000	4,189,000	4,932,000
R&D Expenses	-72.7%	1,218,000	4,454,000	9,595,000	14,328,000	13,424,000	13,380,000	13,589,000	11,947,000	14,066,000	15,357,000	18,937,000	15,800,000	16,562,000	10,618,000	11,822,000	11,333,000	12,758,000	14,116,000	13,211,000	13,373,000	14,296,000
EBITDA Margin	0%	-0.46	-0.46	-0.58	-0.83	-1.67	-1.07	-1.41	-1.47	-1.48	-1.29	-1.29	-1.39	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-771,000	-2,592,000	-11,758,000	-10,348,000
EBT Margin	0%	-0.57	-0.57	-0.70	-1.00	-1.99	-1.29	-1.61	-1.68	-1.70	-1.46	-1.49	-1.56	-	-	-	-	-	-	-	-	-
Net Income	-6.7%	-4,892,000	-4,584,000	-10,752,000	3,976,000	-13,183,000	-8,102,000	-9,736,000	-10,338,000	-5,101,000	-9,532,000	-16,536,000	-15,498,000	-4,172,000	-14,400,000	-14,283,000	-4,950,000	-3,597,000	-771,000	-2,592,000	-11,758,000	-10,348,000
Net Income Margin	33.8%	-0.38	-0.57	-0.59	-0.81	-2.47	-1.29	-1.22	-1.53	-1.73	-1.46	-2.04	-2.04	-	-	-	-	-	-	-	-	-
Free Cashflow	64.4%	-6,996,000	-19,656,000	-9,792,000	-13,498,000	-11,044,000	-12,922,000	-8,812,000	-16,207,000	-23,032,000	-11,286,000	-14,834,000	29,677,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-23.7%	29.00	39.00	59.00	88.00	82.00	95.00	99.00	114	137	154	164	155	116	105	116	118	124	141	117	131	131
Current Assets	-100.0%	-	39.00	59.00	66.00	61.00	73.00	79.00	91.00	112	128	138	128	88.00	76.00	89.00	92.00	98.00	115	98.00	111	124
Cash Equivalents	9.7%	19.00	17.00	33.00	45.00	40.00	39.00	48.00	54.00	84.00	118	125	119	67.00	70.00	67.00	44.00	47.00	62.00	46.00	55.00	52.00
Net PPE	-	-	-	-	16.00	17.00	17.00	16.00	17.00	19.00	19.00	20.00	20.00	21.00	22.00	21.00	21.00	20.00	20.00	11.00	8.00	5.00
Liabilities	-100.0%	-	12.00	29.00	47.00	67.00	68.00	63.00	70.00	84.00	103	110	108	78.00	74.00	72.00	71.00	74.00	90.00	96.00	111	101
Current Liabilities	-36.8%	8.00	12.00	29.00	34.00	43.00	37.00	34.00	36.00	39.00	51.00	50.00	44.00	30.00	22.00	20.00	18.00	20.00	27.00	40.00	41.00	41.00
Shareholder's Equity	-17.9%	22.00	27.00	31.00	40.00	15.00	28.00	1.00	44.00	53.00	51.00	54.00	47.00	38.00	31.00	44.00	47.00	50.00	51.00	21.00	19.00	30.00
Retained Earnings	-1.6%	-319	-314	-310	-299	-303	-290	-282	-272	-262	-257	-247	-231	-215	-211	-197	-182	-177	-174	-173	-170	-159
Additional Paid-In Capital	0.2%	342	342	341	340	319	319	317	316	315	307	303	277	254	243	241	230	229	227	195	193	191
Shares Outstanding	-100.0%	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	11.00	-	-	-	114	-	-	-	171	-	-	-	117	-	-	-	206	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	64.4%	-6,996	-19,669	-9,723	-13,431	-10,996	-12,933	-8,778	-15,578	-22,643	-10,944	-14,484	29,906	-12,138	-13,417	-7,570	-9,778	-15,131	-13,974	-12,652	-10,733	-15,108
Share Based Compensation	4.7%	472	451	966	1,048	884	949	974	1,301	1,178	1,320	1,370	1,326	1,199	1,174	1,396	1,237	1,283	1,114	1,518	1,452	1,290
Cashflow From Investing	160.9%	9,000	3,449	-1,984	-1,366	11,903	1,107	5,470	-10,865	-16,948	-342	-350	-229	-28.00	14,851	18,351	5,596	414	-1,881	4,123	12,912	-5,316
Cashflow From Financing	-100.0%	-	14.00	-	19,781	-	93.00	282	281	6,558	4,901	21,916	22,617	9,693	75.00	9,624	416	-	31,665	221	280	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PIRS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Customer revenue	$ 6	$ 2,010
Collaboration revenue	47	(74)
Total revenue	53	1,936
Operating expenses
Research and development	1,218	13,424
General and administrative	4,138	4,023
Total operating expenses	5,356	17,447
Loss from operations	(5,303)	(15,511)
Other income (expense)
Interest income	240	357
Grant income	0	2,028
Other income (loss)	171	(57)
Net loss	(4,892)	(13,183)
Other comprehensive income loss:
Foreign currency translation	(373)	(242)
Unrealized gain (loss) on available-for-sale securities	(1)	70
Comprehensive loss	$ (5,266)	$ (13,355)
Net loss per share
Basic and diluted (in dollars per share)	$ (3.95)	$ (14.15)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	1,237	931

PIRS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 19,084	$ 17,396
Short term investments	0	8,970
Accounts receivable	1,842	572
Receivable from public grants	3,071	3,141
Other receivables	2,332	2,326
Assets held for sale, property and equipment	196	2,188
Prepaid expenses and other current assets	2,972	4,087
Total current assets	29,497	38,680
Current liabilities:
Accounts payable	1,518	3,372
Accrued expenses and other current liabilities	6,015	8,550
Total current liabilities	7,533	11,922
Stockholders’ equity:
Preferred stock	0	0
Common stock	1	1
Additional paid-in capital	342,165	341,693
Accumulated other comprehensive loss	(346)	28
Accumulated deficit	(319,856)	(314,964)
Total stockholders’ equity	21,964	26,758
Total liabilities and stockholders’ equity	$ 29,497	$ 38,680

About Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

CEO	Mr. Stephen S. Yoder J.D.
WEBSITE	pieris.com
INDUSTRY	Biotechnology
EMPLOYEES	127

Pieris Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Pieris Pharmaceuticals Inc? What does PIRS stand for in stocks?

PIRS is the stock ticker symbol of Pieris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pieris Pharmaceuticals Inc (PIRS)?

As of Fri May 17 2024, market cap of Pieris Pharmaceuticals Inc is 1.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PIRS stock?

You can check PIRS's fair value in chart for subscribers.

What is the fair value of PIRS stock?

You can check PIRS's fair value in chart for subscribers. The fair value of Pieris Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pieris Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PIRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pieris Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PIRS is over valued or under valued. Whether Pieris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Pieris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PIRS.

What is Pieris Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PIRS's PE ratio (Price to Earnings) is -66.78 and Price to Sales (PS) ratio is 25.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PIRS PE ratio will change depending on the future growth rate expectations of investors.